{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:26:13Z","timestamp":1788499573440,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100017962","name":"Jiangsu Provincial Health Commission","doi-asserted-by":"crossref","award":["MQ2024008"],"award-info":[{"award-number":["MQ2024008"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100017962","name":"Jiangsu Provincial Health Commission","doi-asserted-by":"crossref","award":["MQ2024008"],"award-info":[{"award-number":["MQ2024008"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100017962","name":"Jiangsu Provincial Health Commission","doi-asserted-by":"crossref","award":["MQ2024008"],"award-info":[{"award-number":["MQ2024008"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100017962","name":"Jiangsu Provincial Health Commission","doi-asserted-by":"crossref","award":["MQ2024008"],"award-info":[{"award-number":["MQ2024008"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100017962","name":"Jiangsu Provincial Health Commission","doi-asserted-by":"crossref","award":["MQ2024008"],"award-info":[{"award-number":["MQ2024008"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100017962","name":"Jiangsu Provincial Health Commission","doi-asserted-by":"crossref","award":["MQ2024008"],"award-info":[{"award-number":["MQ2024008"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100017962","name":"Jiangsu Provincial Health Commission","doi-asserted-by":"crossref","award":["MQ2024008"],"award-info":[{"award-number":["MQ2024008"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-17061-7","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T09:35:25Z","timestamp":1759397725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Determinants of treatment success and cost implications in MDR\/RR-TB patients: a prospective cohort study in China"],"prefix":"10.1038","volume":"15","author":[{"given":"Meijuan","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"17061_CR1","unstructured":"World Health Organization. Global tuberculosis report 2024. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024 (2024)."},{"key":"17061_CR2","doi-asserted-by":"publisher","first-page":"22361","DOI":"10.1038\/s41598-023-47094-9","volume":"13","author":"TY Akalu","year":"2023","unstructured":"Akalu, T. Y., Clements, A. C. A., Wolde, H. F. & Alene, K. A. Economic burden of multidrug-resistant tuberculosis on patients and households: a global systematic review and meta-analysis. Sci. Rep. 13, 22361. https:\/\/doi.org\/10.1038\/s41598-023-47094-9 (2023).","journal-title":"Sci. Rep."},{"key":"17061_CR3","doi-asserted-by":"publisher","first-page":"e077431","DOI":"10.1136\/bmj-2023-077431","volume":"382","author":"B Basnyat","year":"2023","unstructured":"Basnyat, B. & Caws, M. Prevent TB to end TB. Bmj 382, e077431. https:\/\/doi.org\/10.1136\/bmj-2023-077431 (2023).","journal-title":"Bmj"},{"key":"17061_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3760\/cma.j.cn112147-20221030-00853","volume":"46","author":"JJ Yu","year":"2023","unstructured":"Yu, J. J. & Tang, S. J. Annual progress of chemotherapy of multidrug\/rifampicin-resistant tuberculosis in 2022. Chin. J. Tuberculosis Respiratory Dis. 46, 62\u201366. https:\/\/doi.org\/10.3760\/cma.j.cn112147-20221030-00853 (2023).","journal-title":"Chin. J. Tuberculosis Respiratory Dis."},{"key":"17061_CR5","unstructured":"World Health Organization Guidelines Approved by the Guidelines Review Committee  https:\/\/www.who.int\/groups\/guidelines-review-committee (2019)."},{"key":"17061_CR6","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/s0140-6736(22)02078-5","volume":"400","author":"RL Goodall","year":"2022","unstructured":"Goodall, R. L. et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet 400, 1858\u20131868. https:\/\/doi.org\/10.1016\/s0140-6736(22)02078-5 (2022).","journal-title":"Lancet"},{"key":"17061_CR7","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1056\/NEJMoa2400327","volume":"392","author":"L Guglielmetti","year":"2025","unstructured":"Guglielmetti, L. et al. Oral regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible tuberculosis. N Engl. J. Med. 392, 468\u2013482. https:\/\/doi.org\/10.1056\/NEJMoa2400327 (2025).","journal-title":"N Engl. J. Med."},{"key":"17061_CR8","doi-asserted-by":"publisher","unstructured":"Abidi, S. et al. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. Eur. Respir.  J. 55 https:\/\/doi.org\/10.1183\/13993003.01467-2019 (2020).","DOI":"10.1183\/13993003.01467-2019"},{"key":"17061_CR9","doi-asserted-by":"publisher","first-page":"e0241065","DOI":"10.1371\/journal.pone.0241065","volume":"15","author":"FO Bada","year":"2020","unstructured":"Bada, F. O. et al. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant\/multi-drug resistant tuberculosis in Nigeria. PLoS One. 15, e0241065. https:\/\/doi.org\/10.1371\/journal.pone.0241065 (2020).","journal-title":"PLoS One"},{"key":"17061_CR10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.2471\/blt.19.243584","volume":"98","author":"JJ Madan","year":"2020","unstructured":"Madan, J. J. et al. Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South africa: the STREAM trial. Bull. World Health Organ. 98, 306\u2013314. https:\/\/doi.org\/10.2471\/blt.19.243584 (2020).","journal-title":"Bull. World Health Organ."},{"key":"17061_CR11","doi-asserted-by":"publisher","first-page":"e0217820","DOI":"10.1371\/journal.pone.0217820","volume":"14","author":"C van Rensburg","year":"2019","unstructured":"van Rensburg, C. et al. Cost outcome analysis of decentralized care for drug-resistant tuberculosis in johannesburg, South Africa. PLoS One. 14, e0217820. https:\/\/doi.org\/10.1371\/journal.pone.0217820 (2019).","journal-title":"PLoS One"},{"key":"17061_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.4269\/ajtmh.13-0004","volume":"89","author":"A Bassili","year":"2013","unstructured":"Bassili, A. et al. A systematic review of the effectiveness of hospital- and ambulatory-based management of multidrug-resistant tuberculosis. Am. J. Trop. Med. Hyg. 89, 271\u2013280. https:\/\/doi.org\/10.4269\/ajtmh.13-0004 (2013).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"17061_CR13","doi-asserted-by":"publisher","first-page":"e54587","DOI":"10.1371\/journal.pone.0054587","volume":"8","author":"A Pooran","year":"2013","unstructured":"Pooran, A., Pieterson, E., Davids, M., Theron, G. & Dheda, K. What is the cost of diagnosis and management of drug resistant tuberculosis in South africa?? PLoS One. 8, e54587. https:\/\/doi.org\/10.1371\/journal.pone.0054587 (2013).","journal-title":"PLoS One"},{"key":"17061_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.tube.2017.01.002","volume":"103","author":"F Di Gennaro","year":"2017","unstructured":"Di Gennaro, F. et al. Social determinants of therapy failure and multi drug resistance among people with tuberculosis: A review. Tuberculosis (Edinb). 103, 44\u201351. https:\/\/doi.org\/10.1016\/j.tube.2017.01.002 (2017).","journal-title":"Tuberculosis (Edinb)"},{"key":"17061_CR15","doi-asserted-by":"publisher","first-page":"e0226507","DOI":"10.1371\/journal.pone.0226507","volume":"14","author":"NM Chaves Torres","year":"2019","unstructured":"Chaves Torres, N. M., Rodr\u00edguez, Q., Andrade, J. J. P., Arriaga, P. S., Netto, E. M. & M. B. & Factors predictive of the success of tuberculosis treatment: A systematic review with meta-analysis. PLoS One. 14, e0226507. https:\/\/doi.org\/10.1371\/journal.pone.0226507 (2019).","journal-title":"PLoS One"},{"key":"17061_CR16","doi-asserted-by":"publisher","first-page":"e1001675","DOI":"10.1371\/journal.pmed.1001675","volume":"11","author":"T Wingfield","year":"2014","unstructured":"Wingfield, T. et al. Defining catastrophic costs and comparing their importance for adverse tuberculosis outcome with multi-drug resistance: a prospective cohort study, Peru. PLoS Med. 11, e1001675. https:\/\/doi.org\/10.1371\/journal.pmed.1001675 (2014).","journal-title":"PLoS Med."},{"key":"17061_CR17","doi-asserted-by":"publisher","unstructured":"Kafie, C. et al. Cost and cost-effectiveness of digital technologies for support of tuberculosis treatment adherence: a systematic review. BMJ Glob. Health  9 https:\/\/doi.org\/10.1136\/bmjgh-2024-015654 (2024).","DOI":"10.1136\/bmjgh-2024-015654"},{"key":"17061_CR18","doi-asserted-by":"publisher","first-page":"736986","DOI":"10.3389\/fphar.2021.736986","volume":"12","author":"JY Byun","year":"2021","unstructured":"Byun, J. Y., Kim, H. L., Lee, E. K. & Kwon, S. H. A systematic review of economic evaluations of active tuberculosis treatments. Front. Pharmacol. 12, 736986. https:\/\/doi.org\/10.3389\/fphar.2021.736986 (2021).","journal-title":"Front. Pharmacol."},{"key":"17061_CR19","doi-asserted-by":"publisher","unstructured":"Falzon, D. et al. World health organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur. Respir.  J. 49 https:\/\/doi.org\/10.1183\/13993003.02308-2016 (2017).","DOI":"10.1183\/13993003.02308-2016"},{"key":"17061_CR20","unstructured":"World Health Organization Consolidated Guidelines on drug-resistant Tuberculosis Treatment (World Health Organization, (2019)."},{"key":"17061_CR21","doi-asserted-by":"publisher","first-page":"2344821","DOI":"10.1080\/07853890.2024.2344821","volume":"56","author":"P Gu","year":"2024","unstructured":"Gu, P. et al. Effectiveness, cost, and safety of four regimens recommended by WHO for RR\/MDR-TB treatment: a cohort study in Eastern China. Ann. Med. 56, 2344821. https:\/\/doi.org\/10.1080\/07853890.2024.2344821 (2024).","journal-title":"Ann. Med."},{"key":"17061_CR22","doi-asserted-by":"publisher","unstructured":"Linh, N. N. et al. World health organization treatment outcome definitions for tuberculosis: 2021 update. Eur. Respir. J. 58 https:\/\/doi.org\/10.1183\/13993003.00804-2021 (2021).","DOI":"10.1183\/13993003.00804-2021"},{"key":"17061_CR23","unstructured":"In WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment - Drug-Resistant Tuberculosis Treatment (World Health Organization \u00a9 World Health Organization 2020)."},{"key":"17061_CR24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez, A., Santana, N., Arias-Santiago, S. & Viera, A. Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 112, 90\u201392. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009 (2021).","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"17061_CR25","doi-asserted-by":"publisher","first-page":"e1001693","DOI":"10.1371\/journal.pmed.1001693","volume":"11","author":"K L\u00f6nnroth","year":"2014","unstructured":"L\u00f6nnroth, K. et al. Beyond UHC: monitoring health and social protection coverage in the context of tuberculosis care and prevention. PLoS Med. 11, e1001693. https:\/\/doi.org\/10.1371\/journal.pmed.1001693 (2014).","journal-title":"PLoS Med."},{"key":"17061_CR26","doi-asserted-by":"publisher","unstructured":"Xie Lei, X., Yanjun, H. Y. & Hua, W. Influencing factors of treatment outcome in 178 patients with multi-drug resistant pulmonary tuberculosis. Health Med. Res. Prac.  20 https:\/\/doi.org\/10.11986\/j.issn.1673-873X.2023.07.010 (2023).","DOI":"10.11986\/j.issn.1673-873X.2023.07.010"},{"key":"17061_CR27","doi-asserted-by":"publisher","first-page":"e1002595","DOI":"10.1371\/journal.pmed.1002595","volume":"15","author":"N Alipanah","year":"2018","unstructured":"Alipanah, N. et al. Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies. PLoS Med. 15, e1002595. https:\/\/doi.org\/10.1371\/journal.pmed.1002595 (2018).","journal-title":"PLoS Med."},{"key":"17061_CR28","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2471\/blt.23.290396","volume":"102","author":"A Chauhan","year":"2024","unstructured":"Chauhan, A. et al. Health literacy and tuberculosis control: systematic review and meta-analysis. Bull. World Health Organ. 102, 421\u2013431. https:\/\/doi.org\/10.2471\/blt.23.290396 (2024).","journal-title":"Bull. World Health Organ."},{"key":"17061_CR29","doi-asserted-by":"publisher","first-page":"719","DOI":"10.5588\/ijtld.12.0638","volume":"17","author":"CM Denkinger","year":"2013","unstructured":"Denkinger, C. M. et al. Mobile health to improve tuberculosis care and control: a call worth making. Int. J. Tuberc Lung Dis. 17, 719\u2013727. https:\/\/doi.org\/10.5588\/ijtld.12.0638 (2013).","journal-title":"Int. J. Tuberc Lung Dis."},{"key":"17061_CR30","doi-asserted-by":"publisher","first-page":"e1001362","DOI":"10.1371\/journal.pmed.1001362","volume":"10","author":"C Free","year":"2013","unstructured":"Free, C. et al. The effectiveness of mobile-health technology-based health behaviour change or disease management interventions for health care consumers: a systematic review. PLoS Med. 10, e1001362. https:\/\/doi.org\/10.1371\/journal.pmed.1001362 (2013).","journal-title":"PLoS Med."},{"key":"17061_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40249-021-00809-4","volume":"10","author":"Q Long","year":"2021","unstructured":"Long, Q. et al. Multi-source financing for tuberculosis treatment in china: key issues and challenges. Infect. Dis. Poverty. 10, 17. https:\/\/doi.org\/10.1186\/s40249-021-00809-4 (2021).","journal-title":"Infect. Dis. Poverty"},{"key":"17061_CR32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jinf.2018.10.004","volume":"77","author":"IS Pradipta","year":"2018","unstructured":"Pradipta, I. S., Forsman, L. D., Bruchfeld, J., Hak, E. & Alffenaar, J. W. Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis. J. Infect. 77, 469\u2013478. https:\/\/doi.org\/10.1016\/j.jinf.2018.10.004 (2018).","journal-title":"J. Infect."},{"key":"17061_CR33","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/trstmh\/traa038","volume":"114","author":"A Fuady","year":"2020","unstructured":"Fuady, A., Houweling, T. A. J., Mansyur, M., Burhan, E. & Richardus, J. H. Catastrophic costs due to tuberculosis worsen treatment outcomes: a prospective cohort study in Indonesia. Trans. R Soc. Trop. Med. Hyg. 114, 666\u2013673. https:\/\/doi.org\/10.1093\/trstmh\/traa038 (2020).","journal-title":"Trans. R Soc. Trop. Med. Hyg."},{"key":"17061_CR34","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.2147\/ppa.S389231","volume":"16","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. Impacts of medical security level on treatment outcomes of Drug-Resistant tuberculosis: evidence from Wuhan city, China. Patient Prefer Adherence. 16, 3341\u20133355. https:\/\/doi.org\/10.2147\/ppa.S389231 (2022).","journal-title":"Patient Prefer Adherence"},{"key":"17061_CR35","doi-asserted-by":"publisher","unstructured":"Plesca, V., Ciobanu, A., Sereda, Y. & Dadu, A. Do catastrophic costs impact treatment outcomes in people with rifampicin-resistant tuberculosis in the Republic of moldova?? Monaldi Arch. Chest Dis. 91 https:\/\/doi.org\/10.4081\/monaldi.2021.1650 (2021).","DOI":"10.4081\/monaldi.2021.1650"},{"key":"17061_CR36","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1186\/s12889-024-19609-0","volume":"24","author":"MP Rupani","year":"2024","unstructured":"Rupani, M. P., Vyas, S. & Shah, I. A. Cohort study on association between catastrophic costs and unfavorable tuberculosis treatment outcomes among TB-HIV and TB-diabetes comorbid patients in India. BMC Public. Health. 24, 2028. https:\/\/doi.org\/10.1186\/s12889-024-19609-0 (2024).","journal-title":"BMC Public. Health"},{"key":"17061_CR37","doi-asserted-by":"publisher","first-page":"469580231224823","DOI":"10.1177\/00469580231224823","volume":"61","author":"P Cao","year":"2024","unstructured":"Cao, P. & Pan, J. Understanding factors influencing geographic variation in healthcare expenditures: A small areas analysis study. Inquiry 61, 469580231224823. https:\/\/doi.org\/10.1177\/00469580231224823 (2024).","journal-title":"Inquiry"},{"key":"17061_CR38","doi-asserted-by":"publisher","unstructured":"Wang, X. et al. Disparity in healthcare seeking behaviors between impoverished and non-impoverished populations with implications for healthcare resource optimization. Humanit. Soc.  Sci. Commun. 11 https:\/\/doi.org\/10.1057\/s41599-024-03712-z (2024).","DOI":"10.1057\/s41599-024-03712-z"},{"key":"17061_CR39","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ijtb.2019.11.005","volume":"66","author":"R Prasad","year":"2019","unstructured":"Prasad, R., Singh, A. & Gupta, N. Adverse drug reactions in tuberculosis and management. Indian J. Tuberc. 66, 520\u2013532. https:\/\/doi.org\/10.1016\/j.ijtb.2019.11.005 (2019).","journal-title":"Indian J. Tuberc"},{"key":"17061_CR40","doi-asserted-by":"publisher","first-page":"19880","DOI":"10.1038\/s41598-023-46565-3","volume":"13","author":"P Akkahadsee","year":"2023","unstructured":"Akkahadsee, P., Sawangjit, R., Phumart, P., Chaiyakunapruk, N. & Sakloetsakun, D. Systematic review and network meta-analysis of efficacy and safety of interventions for preventing anti-tuberculosis drug induced liver injury. Sci. Rep. 13, 19880. https:\/\/doi.org\/10.1038\/s41598-023-46565-3 (2023).","journal-title":"Sci. Rep."},{"key":"17061_CR41","doi-asserted-by":"publisher","unstructured":"Soeroto, A. Y. et al. Comparison of serum potassium, magnesium, and calcium levels between kanamycin and capreomycin-based regimen-treated multidrug-resistant tuberculosis patients in Bandung (CEASE MDR-TB): A retrospective cohort study. Int. J. Microbiol. 2019 5065847. https:\/\/doi.org\/10.1155\/2019\/5065847 (2019).","DOI":"10.1155\/2019\/5065847"},{"key":"17061_CR42","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.5001\/omj.2021.38","volume":"36","author":"MO Khalil","year":"2021","unstructured":"Khalil, M. O., Al-Tikrity, M. A., Saffo, H. A. & Yassin, M. A. Severe hypokalemia as a rare presentation of disseminated tuberculosis. Oman Med. J. 36, e328. https:\/\/doi.org\/10.5001\/omj.2021.38 (2021).","journal-title":"Oman Med. J."},{"key":"17061_CR43","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ijtb.2020.07.017","volume":"67","author":"T Umumararungu","year":"2020","unstructured":"Umumararungu, T. et al. A review of recent advances in anti-tubercular drug development. Indian J. Tuberc. 67, 539\u2013559. https:\/\/doi.org\/10.1016\/j.ijtb.2020.07.017 (2020).","journal-title":"Indian J. Tuberc"},{"key":"17061_CR44","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1590\/s1806-37132015000100010","volume":"41","author":"LS Resende","year":"2015","unstructured":"Resende, L. S. & Santos-Neto, E. T. Risk factors associated with adverse reactions to antituberculosis drugs. J. Bras. Pneumol. 41, 77\u201389. https:\/\/doi.org\/10.1590\/s1806-37132015000100010 (2015).","journal-title":"J. Bras. Pneumol"},{"key":"17061_CR45","doi-asserted-by":"publisher","first-page":"9400","DOI":"10.1038\/s41467-024-53273-7","volume":"15","author":"VK Chang","year":"2024","unstructured":"Chang, V. K. et al. Risk-stratified treatment for drug-susceptible pulmonary tuberculosis. Nat. Commun. 15, 9400. https:\/\/doi.org\/10.1038\/s41467-024-53273-7 (2024).","journal-title":"Nat. Commun."},{"key":"17061_CR46","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s12916-020-01770-z","volume":"18","author":"PPJ Phillips","year":"2020","unstructured":"Phillips, P. P. J. et al. Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial. BMC Med. 18, 314. https:\/\/doi.org\/10.1186\/s12916-020-01770-z (2020).","journal-title":"BMC Med."},{"key":"17061_CR47","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1164\/rccm.202107-1779OC","volume":"205","author":"A Esmail","year":"2022","unstructured":"Esmail, A. et al. An All-Oral 6-Month regimen for Multidrug-Resistant tuberculosis: A multicenter, randomized controlled clinical trial (the next Study). Am. J. Respir Crit. Care Med. 205, 1214\u20131227. https:\/\/doi.org\/10.1164\/rccm.202107-1779OC (2022).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"17061_CR48","doi-asserted-by":"publisher","unstructured":"Tr\u00e9bucq, A. et al. Short-course regimen for multidrug-resistant tuberculosis: A decade of evidence. J. Clin. Med. 9 https:\/\/doi.org\/10.3390\/jcm9010055 (2019).","DOI":"10.3390\/jcm9010055"},{"key":"17061_CR49","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","volume":"380","author":"AJ Nunn","year":"2019","unstructured":"Nunn, A. J. et al. A trial of a shorter regimen for Rifampin-Resistant tuberculosis. N Engl. J. Med. 380, 1201\u20131213. https:\/\/doi.org\/10.1056\/NEJMoa1811867 (2019).","journal-title":"N Engl. J. Med."},{"key":"17061_CR50","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","volume":"200","author":"P Nahid","year":"2019","unstructured":"Nahid, P. et al. Treatment of Drug-Resistant tuberculosis. An official ATS\/CDC\/ERS\/IDSA clinical practice guideline. Am. J. Respir Crit. Care Med. 200, e93\u2013e142. https:\/\/doi.org\/10.1164\/rccm.201909-1874ST (2019).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"17061_CR51","doi-asserted-by":"publisher","unstructured":"Ahmad Khan, F. et al. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses. Eur. Respir.  J. 50 https:\/\/doi.org\/10.1183\/13993003.00061-2017 (2017).","DOI":"10.1183\/13993003.00061-2017"},{"key":"17061_CR52","unstructured":"In WHO consolidated guidelines on tuberculosis: Module 4: treatment - Drug-Resistant Tuberculosis Treatment, 2022 Update (World Health Organization \u00a9 World Health Organization 2022)."},{"key":"17061_CR53","doi-asserted-by":"publisher","first-page":"107230","DOI":"10.1016\/j.ijid.2024.107230","volume":"148","author":"L Song","year":"2024","unstructured":"Song, L. et al. Assessing hepatotoxicity in novel and standard short regimens for rifampicin-resistant tuberculosis: insights from the TB-TRUST and TB-TRUST-plus trials. Int. J. Infect. Dis. 148, 107230. https:\/\/doi.org\/10.1016\/j.ijid.2024.107230 (2024).","journal-title":"Int. J. Infect. Dis."},{"key":"17061_CR54","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/cid\/ciy1105","volume":"69","author":"ANH Bulabula","year":"2019","unstructured":"Bulabula, A. N. H. et al. Prevalence, predictors, and successful treatment outcomes of Xpert MTB\/RIF-identified Rifampicin-resistant tuberculosis in Post-conflict Eastern Democratic Republic of the congo, 2012\u20132017: A retrospective Province-Wide cohort study. Clin. Infect. Dis. 69, 1278\u20131287. https:\/\/doi.org\/10.1093\/cid\/ciy1105 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"17061_CR55","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee  https:\/\/www.who.int\/groups\/guidelines-review-committee (2016)."},{"key":"17061_CR56","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1371\/journal.pmed.0040238","volume":"4","author":"SA Munro","year":"2007","unstructured":"Munro, S. A. et al. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med. 4, e238. https:\/\/doi.org\/10.1371\/journal.pmed.0040238 (2007).","journal-title":"PLoS Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17061-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17061-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17061-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T09:35:30Z","timestamp":1759397730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17061-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["17061"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-17061-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Jiangsu Provincial Center for Disease Control and Prevention (Approval No. JSJK2023-B022-01). All experimental protocols involving human participants complied with relevant guidelines and regulations. Clinical Trial Registration: Not applicable. Clinical trial number: not applicable. Written informed consent was obtained from all participants prior to their inclusion in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"34370"}}